Display options
Share it on

Plast Reconstr Surg Glob Open. 2021 Jan 25;9(1):e3372. doi: 10.1097/GOX.0000000000003372. eCollection 2021 Jan.

Botulinum Toxin Type A as a Tool for Correcting Capsular Contracture after Reconstructive Breast Surgery.

Plastic and reconstructive surgery. Global open

Aziz D Zikiryakhodzhaev, Galina S Alekseeva, Igor V Reshetov, Marianna V Starkova, Eric K Saribekyan, Fedor N Usov, Maria Yu Vlasova

Affiliations

  1. Department of Oncology and Reconstuctive Plastic Surgery of Breast and Skin, P.A. Hertsen Moscow Oncology Research Center, Moscow, Russian Federation.
  2. Federal State Autonomous Educational Institution for Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Moscow, Russian Federation.

PMID: 33552818 PMCID: PMC7861963 DOI: 10.1097/GOX.0000000000003372

Abstract

Capsular contracture is one of the most common complications after breast reconstruction. Surgical treatment is the main option for capsular contracture correction and includes capsulotomy, capsulectomy, and removal/replacement of the affected implant. However, the surgical trauma from reoperation, along with reduced quality of life, in patients with clinically significant capsular contracture has prompted a search for alternative treatment options. The use of the botulinum toxin type A in the treatment of neurological diseases and of keloid scars in aesthetic practice nudged the idea of using the same toxin for the correction of capsular contractures in breast cancer patients. Botulinum toxin type A injection is an easy procedure requiring no anesthesia or inpatient care. The treatment has few side effects. In addition, the injection does not cause sensory loss or dysesthesia. We described a clinical case of the capsular contracture correction using incobotulinumtoxin A. Capsular contracture IV developed 4 months post surgery after long-term lymphorrhea. Radiation therapy was not performed. According to the internal protocol, the patient was advised to undergo incobotulinumtoxin A treatment instead of surgery. Within 1 week after the second injection, all symptoms decreased-specifically, the general shape of the reconstructed breast. Also, the pain syndrome disappeared.

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.

Conflict of interest statement

Disclosure: The authors have no financial interest to declare in relation to the content of this article. No funding was received for this article.

References

  1. Plast Reconstr Surg. 2015 Aug;136(2):171e-178e - PubMed
  2. Aesthetic Plast Surg. 2019 Feb;43(1):70-75 - PubMed
  3. J Plast Reconstr Aesthet Surg. 2013 Mar;66(3):439-40 - PubMed
  4. Aesthet Surg J. 2019 Jul 12;39(8):848-859 - PubMed
  5. Aesthetic Plast Surg. 2007 Jul-Aug;31(4):330-6 - PubMed
  6. Ann Plast Surg. 2003 Dec;51(6):531-9 - PubMed
  7. Plast Reconstr Surg. 2016 Nov;138(5):821e-829e - PubMed
  8. Arch Facial Plast Surg. 2006 Nov-Dec;8(6):362-8 - PubMed
  9. Plast Reconstr Surg. 2019 Mar;143(3):760-767 - PubMed
  10. Natl J Maxillofac Surg. 2016 Jan-Jun;7(1):10-16 - PubMed
  11. J Plast Reconstr Aesthet Surg. 2016 Apr;69(4):452-60 - PubMed
  12. Plast Reconstr Surg. 2006 Mar;117(3):757-67; discussion 768-72 - PubMed
  13. Surg Clin North Am. 2018 Aug;98(4):835-844 - PubMed
  14. Aesthetic Plast Surg. 2007 Sep-Oct;31(5):532-9 - PubMed
  15. Plast Reconstr Surg. 2007 Jul;120(1):275-284 - PubMed
  16. Plast Reconstr Surg. 1995 Oct;96(5):1119-23; discussion 1124 - PubMed

Publication Types